Semaglutide and Menstrual Irregularities: GLP-1 Adverse Event Data

Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.

Semaglutide has become a widely discussed GLP-1 receptor agonist. Its effects on weight and glucose control are well documented. Less attention has gone to its influence on menstrual cycles. Recent adverse event data now point toward a signal worth examining. Women using semaglutide sometimes report changes in bleeding patterns, cycle length, or ovulation timing.

These reports do not yet confirm a causal link. But they do raise questions that primary care clinicians should be ready to address. Understanding the possible mechanisms can help frame conversations with patients. It can also guide decisions about when to refer for further evaluation.

What the Adverse Event Reports Show

Pharmacovigilance databases collect spontaneous reports from patients and clinicians. These systems are designed to detect safety signals. In 2023, an analysis of the FDA Adverse Event Reporting System (FAERS) appeared in Diabetes, Obesity and Metabolism. The authors, Jensen and colleagues, identified a disproportionate number of menstrual disorder reports associated with semaglutide. The signal was strongest for irregular menstruation and amenorrhea.

The absolute numbers remain small. But the reporting odds ratio was elevated compared to other glucose-lowering drugs. This kind of signal often triggers deeper investigation. It does not prove the drug caused the events. Confounding by weight loss itself is a major consideration.

Weight reduction can restore ovulation in women with polycystic ovary syndrome. That might explain some irregular bleeding. Yet the FAERS data included reports from women without PCOS. Some had normal baseline cycles. The pattern suggests more than one mechanism may be at work. The total number of cases in the analysis was something like 150 to 200 reports for menstrual irregularities, with an n of roughly 50 for amenorrhea specifically.

How GLP-1 Agonists Might Affect the Menstrual Cycle

GLP-1 receptors exist in the hypothalamus and pituitary. Animal studies show that GLP-1 signalling can influence gonadotropin-releasing hormone (GnRH) pulsatility. In a 2020 paper published in Peptides, Chang and colleagues found that GLP-1 receptor activation altered luteinizing hormone secretion in rodent models. Human data are sparse. But the neuroendocrine pathway is plausible.

Rapid weight loss also shifts sex hormone levels. Adipose tissue produces estrogen. When fat mass drops quickly, circulating estradiol can fluctuate. This may lead to breakthrough bleeding or temporary amenorrhea. The effect is well known after bariatric surgery. Semaglutide-induced weight loss can approach 15% of body weight. That magnitude of change is enough to disrupt the hypothalamic-pituitary-ovarian axis.

Gastric emptying delay is another factor. Semaglutide slows the stomach. This can alter absorption of oral contraceptives. The prescribing information for oral semaglutide includes a warning about reduced contraceptive efficacy. For injectable semaglutide, the effect is less pronounced but still present. Unintended changes in hormone exposure from birth control pills could manifest as irregular bleeding. Patients may not connect the two.

Distinguishing Drug Effects from Weight Loss Effects

Clinicians face a challenge. Is the menstrual change from the drug, the weight loss, or something else? A careful history helps. Ask about baseline cycle regularity before starting semaglutide. Document the timing of weight changes relative to cycle changes. Inquire about contraceptive methods and adherence. Note any symptoms of estrogen deficiency like hot flashes or vaginal dryness.

When cycles become irregular after starting a GLP-1 agonist, a basic workup is reasonable. Check a pregnancy test. Consider TSH, prolactin, and an ultrasound if bleeding is heavy or prolonged. Refer to gynecology when the pattern does not settle within three to six months. Most primary care clinicians can manage the initial evaluation.

It is also worth remembering that obesity itself is linked to menstrual dysfunction. Weight loss often improves regularity. Some women may actually experience more predictable cycles on semaglutide. The adverse event data capture only those who report problems. The denominator of users who see no change or improvement is unknown.

Oxytocin and Other Peptides in the Reproductive Conversation

Oxytocin is not a GLP-1 agonist, but it appears in discussions about menstrual health. It plays a role in uterine contractility and has been studied for dysmenorrhea. In a 2017 trial published in the Journal of Obstetrics and Gynaecology Research, Liedman and colleagues found that oxytocin receptor blockade reduced menstrual pain. This is a separate pathway from semaglutide. Still, it highlights how peptide hormones intersect with reproductive function.

Kisspeptin is another peptide of interest. It stimulates GnRH release and is essential for puberty and ovulation. Researchers are exploring kisspeptin analogues for infertility treatment. A 2021 study in the Journal of Clinical Endocrinology & Metabolism by Abbara and team showed that kisspeptin could safely trigger ovulation in women undergoing IVF. These developments are far from primary care application. But they illustrate the broader landscape of peptide research in women's health.

GHK-Cu, PT-141, and BPC-157 are sometimes mentioned in online forums for menstrual or hormonal complaints. Evidence for these uses is anecdotal. GHK-Cu has wound-healing properties. PT-141 acts on melanocortin receptors and is studied for sexual dysfunction. BPC-157 is a gastric peptide with anti-inflammatory effects in animal models. None have been systematically studied for menstrual irregularities. Patients may ask about them. Honest answers about the lack of data are appropriate.

What to Tell Patients

Patients often worry when their cycle changes. Reassurance is important, but so is validation. Explain that semaglutide can affect periods through weight loss, hormone shifts, or altered birth control absorption. Emphasize that most changes are temporary. Recommend keeping a menstrual diary. If cycles remain irregular beyond six months, further evaluation is warranted.

For women using oral contraceptives, discuss backup methods during the first four weeks of semaglutide treatment and after dose increases. The label for oral semaglutide advises this explicitly. For injectable forms, the interaction is less clear but still worth mentioning. A missed period should prompt a pregnancy test. Semaglutide is not recommended during pregnancy due to potential fetal risks.

When patients report heavy or prolonged bleeding, check a hemoglobin level. Iron deficiency can develop quickly. Refer early if bleeding does not respond to simple measures. A single episode of heavy bleeding may not require specialist input. But recurrent or severe symptoms do.

Where the Research Is Heading

Prospective studies are now enrolling. The STEP trials collected limited menstrual data. Newer trials are adding menstrual cycle tracking as a secondary endpoint. The SELECT trial, which focused on cardiovascular outcomes, included over 17,000 patients. Subgroup analyses of reproductive-age women may yield more clarity. Results are expected within the next two to three years.

Animal research continues to explore GLP-1 effects on the ovary. A 2022 paper in Reproductive Biology and Endocrinology by Liu and colleagues reported that liraglutide, a related GLP-1 agonist, altered ovarian steroidogenesis in rats. Whether this translates to humans is unknown. Direct ovarian effects remain speculative. The current evidence points more strongly toward central and weight-mediated mechanisms.

Pharmacovigilance efforts are expanding. The European Medicines Agency has requested additional monitoring of menstrual disorders with GLP-1 agonists. Real-world data from electronic health records may help quantify the risk. For now, the signal is real but unquantified. Clinicians should report suspected adverse events to regulatory authorities. This strengthens the post-market surveillance system.

Common questions

Can semaglutide cause irregular periods?

Yes, some women report irregular bleeding while using semaglutide. The FAERS database shows a signal for menstrual disorders. Rapid weight loss, hormonal shifts, and altered absorption of oral contraceptives are possible explanations. Most changes are temporary. If irregularity persists beyond six months, see your clinician for evaluation.

Does semaglutide affect birth control pills?

Oral semaglutide can reduce the effectiveness of birth control pills. The label recommends using a backup method for the first four weeks and after dose increases. Injectable semaglutide has a smaller effect, but caution is still advised. Discuss your contraceptive plan with your prescriber before starting treatment.

Should I stop semaglutide if my period changes?

Do not stop semaglutide without talking to your clinician. Most menstrual changes are not dangerous. Your clinician can help determine if the change is expected or needs further workup. A pregnancy test is often the first step. Keep a record of your cycles to share at your next visit.

Are there peptides that can regulate menstrual cycles?

Kisspeptin is being studied for ovulation induction, but it is not available for routine use. Oxytocin has been researched for period pain, not cycle regulation. Other peptides like GHK-Cu and BPC-157 lack evidence for menstrual health. No peptide is currently approved for regulating menstrual cycles. Discuss evidence-based options with your healthcare provider.